Navigation Links
New Diabetes Research To Be Presented at FOCIS Annual Meeting
Date:6/4/2008

Federation of Clinical Immunology Societies presentations highlight important findings recognized by Juvenile Diabetes Research Foundation awards

BOSTON, June 4 /PRNewswire-USNewswire/ -- The Federation of Clinical Immunology Societies (FOCIS) announces the presentation of awards to two researchers recognizing significant findings related to advancement of Type 1 Diabetes research. The awards will be made following a research symposia on June 5, in conjunction with the 8th annual meeting of the Federation of Clinical Immunology Societies (FOCIS), being held at the Boston Marriott Copley Place, June 5-9. During the FOCIS annual meeting, an international representation of leading scientists will discuss recent advances in the understanding and treating of immune-mediated diseases in a series of 55 educational sessions presented to 1,200 researchers and physicians at FOCIS 2008. The Juvenile Diabetes Research Foundation (JDRF), in conjunction with FOCIS, is the sponsor of the special awards in the area of type 1 diabetes research.

Anti-CD20 therapy delays or prevents recurrent type 1 diabetes

This study, led by Changyun Hu, Yale University School of Medicine, New Haven, CT, shows that therapy with a monoclonal antibody to a marker on B lymphocytes leads to effective therapy of type 1 diabetes in a preclinical model. Similar therapies are known to be effective for some forms of cancer and other autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis, and a current clinical trial sponsored by the National Institutes of Health is evaluating the comparable treatment in young adults newly diagnosed with autoimmune diabetes. Type 1 diabetes is an autoimmune disease where white cells of the immune system attack the insulin-producing beta cells. Current therapy with insulin does not address the underlying cause. The Yale group studied the mechanisms by which anti-CD20 therapy works in diabetes treatment, which has the potential for short-term therapy to lead to long-term benefits--even potential reversal of disease. Other investigators contributing to the new findings are from the University of Bristol, Bristol, United Kingdom.

Glucose levels can accelerate damage to insulin-producing cells

This study, led by Anna Skowera, King's College London, School of Medicine at Guy's, London, United Kingdom earned the second of the special research awards. Dr. Skowera's research identified a type of killer T lymphocyte which responds to a target comprised on a sequence within the precursor of insulin (called preproinsulin). They found that the target sequence is displayed at higher and higher levels by the insulin-producing beta cell as the glucose concentration around it goes up. In other words, the beta cell contributes to its own destruction when it tries to respond to high glucose levels by making more of this target sequence. The findings bring researchers closer to finding the elements causing of beta cell destruction and to strategies for the prevention of this destruction. One important implication of this study is that maintaining good glucose blood levels is very important for regulating the amount of beta cell damage. Other investigators contributing to the new findings include Min Zhao, Guo Cai Huang and Mark Peakman, also of King's College, London.

About Diabetes, JDRF, and FOCIS

Diabetes is the leading cause of kidney failure and adult blindness in the United States, and is the sixth leading cause of death, shortening life expectancy by an average of 7 to 10 years. Approximately 21 million Americans have diabetes, including 3 million with type 1 diabetes.

The JDRF is the leading charitable funder and advocate of type 1 (juvenile diabetes research worldwide. The mission of JDRF is to find a cure for diabetes and its complications through support of research.

FOCIS is a federation made up of 36 professional societies dedicated to improving human health through immunology. The FOCIS annual scientific meeting hosts delegates representing diverse specialties related to clinical immunology including allergy, dermatology, diabetes, genetics, multiple sclerosis, nephrology, oncology, pathology, transplantation and more. This four and one-half day symposium is an energetic working forum for the exchange of cutting-edge science and insights into autoimmune and inflammatory diseases.

For more information about FOCIS 2008 visit http://www.focisnet.org.

Contact: Gail Bast

FOCIS Executive Director

Email: gbast@focisnet.org

Cell: (414) 640-1635


'/>"/>
SOURCE Federation of Clinical Immunology
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. Novo Nordisk Changing Diabetes(R) Bus Boogies into San Francisco on World Tour to Beat Diabetes
2. Long-term pesticide exposure may increase risk of diabetes
3. Discovery of new signal pathway important to diabetes research
4. Insulet Announces Development Agreement for the First Non-Diabetes Drug Delivery Application for the OmniPod System
5. American Diabetes Association Receives $450,000 Grant From Abbott Fund for Latino Community Initiatives
6. Medifast, Inc. to Present at the Canaccord Adams Diabetes & Obesity Conference
7. Metformin increases pathologic complete response rates in breast cancer patients with diabetes
8. International Diabetes Federation Commits to Improving Diabetes Education Globally Through Centres of Education
9. Panel Calls for Better Diabetes Screening
10. International Diabetes Federation grant supports study to prevent type 2 diabetes in India
11. Insulet Corporation to Present at the Canaccord Adams Diabetes & Obesity Conference on June 6, 2008
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... ... Lori G. Cohen and Sara K. Thompson , shareholders in ... Conference Institute’s 21st Drug & Medical Device Litigation Conference , taking place in New ... Cohen, who chairs the firm’s Pharmaceutical, Medical Device & Health Care Litigation Practice and ...
(Date:12/2/2016)... ... December 02, 2016 , ... Advanced Inc., a leading provider of travel ... CPA, MBA to serve as Advanced Inc.’s Chief Financial Officer, effective December 1, 2016. ... brings extensive financial and operational leadership experience to Advanced Inc. He began his career ...
(Date:12/2/2016)... ... 2016 , ... With the number of pain management programs available for people ... the one that works for them. When an inventor from Suisun City, Calif., was ... decided to share it with others. , He developed a prototype for PRO GO ...
(Date:12/2/2016)... Delaware (PRWEB) , ... December 02, 2016 , ... ... released a new version of its SaaS LIMS, CloudLIMS Lite. CloudLIMS Lite helps ... sample entry through labeling, storing, shipping and disposal. The new version is a ...
(Date:12/2/2016)... , ... December 02, 2016 , ... Yisrayl Hawkins, at ... into how this current generation fits into Bible Prophecy. Yisrayl says this generation, known ... pointing to this conclusion, showing how the details line up exactly with Bible Prophecy ...
Breaking Medicine News(10 mins):
(Date:12/2/2016)... GARDENS, N.Y. , Dec. 2, 2016  LifeVac, ... will be included in the Emergency Response Training and ... are very excited to have LifeVac become part of ... Lih , Founder and CEO of LifeVac. "Having an ... LifeVac safely and effectively will help leverage our efforts ...
(Date:12/2/2016)... Dec. 2, 2016  PipelineRx, a leading medication management ... offering demonstrations of its SaaS-based telepharmacy platform, ... Pharmacists 2016 Midyear Clinical Meeting and Exhibition, December ... With nearly 300 hospital clients nationally, the Company ... designed to dramatically improve pharmacy operations, enhance patient ...
(Date:12/2/2016)...  Maxor National Pharmacy Services, LLC ("Maxor"), today announced that ... The combination of Texas -based Maxor Specialty ... bring together both company,s clinical expertise and high-touch patient service ... specialty pharmacy. About Maxor ... , , ...
Breaking Medicine Technology: